| Autor: |
Choudhary, Vaibhav, Gupta, Sudeep |
| Zdroj: |
Current Breast Cancer Reports; Jun2016, Vol. 8 Issue 2, p53-59, 7p |
| Abstrakt: |
Recent advances in molecular biology have led to unprecedented innovations in diagnosis and treatment of breast cancer. The advent of genomics has revolutionized our understanding of breast cancer. It is no longer considered a single disease but several different biologically and molecularly distinct entities. This research has led to commercially available polymerase chain reaction (PCR)-, microarray-, and next generation sequencing (NGS)-based tests which have changed the way oncologists estimate recurrence risk in early stage breast cancer patients. The genomics era has altered the clinicopathologic paradigm of selecting patients for adjuvant cytotoxic chemotherapy. Numerous well designed prospective studies are underway that may establish these molecular assays as basic elements of standard clinical practice in breast cancer diagnostics and therapeutics. In this article, we review the robustnesses and constraints of currently available breast cancer-specific molecular tests and their clinical ramifications. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink